Quarterly ResultMay 15, 2026, 04:29 PM
Aspire Biopharma Q1 Net Loss Narrows to $3.22M; Cash Up to $5.86M
AI Summary
Aspire Biopharma Holdings, Inc. reported a significant reduction in net loss for the three months ended March 31, 2026, narrowing to $3.22 million from $15.94 million in the prior year. The company also generated its first net revenue of $28,353. Cash and cash equivalents substantially increased to $5.86 million, and total stockholders' equity turned positive, driven by successful financing activities including the issuance of convertible preferred stock and debentures. Management believes current liquidity is sufficient to fund operations for at least one year.
Key Highlights
- Net loss for Q1 2026 narrowed to $3,222,892 from $15,941,328 in Q1 2025.
- Cash and cash equivalents increased to $5,857,024 as of March 31, 2026, from $1,003,904.
- Total stockholders' equity improved to $3,868,463 from a $(6,376,329) deficit.
- Net revenue for Q1 2026 was $28,353, compared to $0 in Q1 2025.
- Total operating expenses decreased significantly to $1,651,919 from $15,556,480.
- Received $6.78 million from convertible preferred stock in February 2026 and $9 million in April 2026.
- Working capital stood at $3,964,715 as of March 31, 2026.
- Company effected 1-for-40 reverse stock split on Jan 16, 2026, and 1-for-30 on May 11, 2026.
Price Impact
More from ASBP